表紙:組織学および細胞学IVD市場:2024年
市場調査レポート
商品コード
1482480

組織学および細胞学IVD市場:2024年

Histology and Cytology IVD Market Update, 2024

出版日: | 発行: Kalorama Information | ページ情報: 英文 80 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
組織学および細胞学IVD市場:2024年
出版日: 2024年05月22日
発行: Kalorama Information
ページ情報: 英文 80 Pages
納期: 即日から翌営業日
担当者のコメント
2023年から2028年までの市場予測、新たな技術開発トレンド、競合分析を提供します。以下5つのセグメントごとに分析されたレポートです。Traditional Non-PAP Stains、PAP、In Situ Hybridization、Immunohistochemistry、HPV
  • 全表示
  • 概要
  • 目次
概要

組織学と細胞学は、細胞、組織、臓器に関する重要な洞察を提供し、病理検査室にとって長い間不可欠な要素でした。病理組織検査を通じて、がんを含む様々な疾患を正確に診断することができます。医師は治療計画や予後を決定するために病理学的情報に大きく依存しています。

最近の技術の進歩は、組織や臓器の構造と機能の関係や、疾患との関連についての理解を著しく深めました。デジタル画像、定量顕微鏡、精密顕微鏡、人工知能、バーチャル組織学などの技術革新は、組織学/細胞学業界に革命をもたらし、精度の向上とワークフローの自動化を実現しようとしています。

当レポートでは、組織学および細胞学IVD市場について調査し、2023年の市場の現状と、2028年までの予測を掲載しています。その他、競合分析や地域別動向も掲載しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 組織学/細胞学の概要
  • 組織学とがん
  • 高度な分析ソリューション
  • 研究室開発テスト
  • AIと組織学

第3章 市場規模と成長

  • 市場セグメント
  • 伝統的な組織染色
  • PAP検査
  • 免疫組織化学とin situハイブリダイゼーション
  • HPV
  • 地域別市場
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域
  • 競合分析
  • 組織学の商業的展望

第4章 主要な市場参入企業

  • Abbott Diagnostics
  • Agilent
  • Becton, Dickinson and Company
  • Biocare Medical
  • BioGenex
  • Danaher Corporation
  • Hologic
  • Illumina, Inc
  • Medimeas
  • QIAGEN N.V.
  • Roche Diagnostic
  • Sysmex
  • Thermo Fisher Scientific
目次
Product Code: 24-035

"Histology and Cytology IVD Market Update, 2024" provides an in-depth competitive analysis of the histology/cytology market from 2023 to 2028. The forecasted market analysis from 2023 to 2028 is based on demographic trends, new technological developments, innovative products, and global market expansion. This comprehensive review offers insights into the future direction of the histology and cytology IVD market, highlighting the potential for growth and advancements.

Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.

Technological Advancements

Recent technological advancements have significantly enhanced the understanding of tissue and organ structure-function relationships and their link to diseases. Innovations such as digital imaging, quantitative microscopy, precision microscopy, artificial intelligence, and virtual histology are set to revolutionize the histology/cytology industry, improving accuracy and automating workflows.

Market Segmentation

This report exclusively focuses on traditional histology and segments the market into five key areas:

  • Traditional Non-PAP Stains
  • PAP
  • In Situ Hybridization
  • Immunohistochemistry
  • HPV

Key Market Participants

The report also profiles five leading companies in the market:

  • Agilent
  • Danaher Corporation
  • Hologic
  • Illumina
  • Roche Diagnostics

Market Data

All market data pertains to the global market at the manufacturers' level, focusing on manufacturer tests. The base year for data is 2023, with projections for 2028. The report provides compound annual growth rates (CAGRs) for 2023-2028. Additionally, competitive analysis and regional breakdowns for the United States, Europe, Asia-Pacific, and the Rest of the World are included.

Table of Contents

Chapter 1: Executive Summary

  • Industry at a Glance
  • Scope and Methodology
  • Size and Growth of the Market
    • Figure 1-1: Global Histology IVD Market, 2023-2028 ($ millions)
  • Competitive Outlook

Chapter 2: Market Overview

  • Overview Of Histology/Cytology
  • Histology and Cancer
  • Advanced Analysis Solutions
    • Table 2-1: Selected Advanced Histology Techniques
  • Laboratory Developed Tests
  • AI and Histology

Chapter 3: Market Size and Growth

  • Market Segments
    • Table 3-1: Global Histology/Cytology Sales, by Type (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023-2028 ($ millions)
    • Figure 3-1: Global Histology/Cytology IVD Market, 2023-2028 ($ millions)
    • Figure 3-2: Histology/Cytology Diagnostic Market Distribution, by Broad Test Category (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023 (%)
  • Traditional Tissue Stains
    • Table 3-2: Selected Vendors of Traditional Histology Stains
  • PAP Tests
    • Table 3-3: Primary and Secondary Prevention of Cervical Cancer, Screening Responses by Country, 2022 (last updated 2022-5-6)
  • Immunohistochemistry and In Situ Hybridization
    • Table 3-4: Selected in Situ Hybridization-based Tests
    • Table 3-5: Selected IHC Test Innovations
  • HPV
    • Figure 3-3: HPV Screening Market: HPV DNA and Pap Test Distribution of Sales, 2023
    • Table 3-6: Global HPV Molecular (DNA/RNA) Test Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
    • Table 3-7: Selected HPV Test Innovations
  • Market by Region
    • Table 3-8: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 ($ millions)
    • Figure 3-4: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 (%)
    • Table 3-9: Global Histology/Cytology Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
  • North America
    • Table 3-10: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-5: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Europe
    • Table 3-11: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-6: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Asia Pacific
    • Table 3-12: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-7: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Rest of World (RoW)
    • Table 3-13: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-8: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Competitive Analysis
    • Table 3-14: Revenues of the Major Histology Companies, 2017-2023 ($ millions, estimated)
    • Table 3-15: Pathology Launches by Roche
  • The Commercial Outlook for Histology

Chapter 4: Major Market Participants

  • Abbott Diagnostics
    • Table 4-1: Abbott Corporate Summary
    • Table 4-2: Abbott Revenue History, 2017-2023 ($ million)
  • Agilent
    • Table 4-3: Agilent Corporate Summary
    • Table 4-4: Agilent Diagnostic Revenues, 2017-2023 ($ millions)
    • Figure 4-1: Agilent Revenues, by Group, 2022-2023 ($ millions)
  • Becton, Dickinson and Company
    • Table 4-5: Becton Dickinson Corporate Summary
    • Table 4-6: BD Revenue History, 2017-2023 ($ million, FYE Sept 30)
  • Biocare Medical
    • Table 4-7: Biocare Medical Corporate Summary
  • BioGenex
    • Table 4-8: BioGenex Corporate Summary
  • Danaher Corporation
    • Table 4-9: Danaher Corporation Summary
    • Table 4-10: Danaher Revenue History, 2017-2023 ($ million, estimated)
    • Figure 4-2: Danaher Diagnostics (Recurring/Nonrecurring), Full Year 2022 and 2023 ($ millions)
  • Hologic
    • Table 4-11: Hologic Corporate Summary
    • Table 4-12: Hologic Revenue History, 2017-2023 ($ million, estimated)
    • Figure 4-3: Hologic Diagnostic Product Revenues, FY 2022 and FY 2023 ($ million)
  • Illumina, Inc
    • Table 4-13: Illumina Corporate Summary
    • Table 4-14: Illumina Diagnostics Revenues, 2017-2023 ($ millions)
    • Figure 4-4: Illumina Diagnostic Revenues, 2022-2023 ($ millions)
  • Medimeas
    • Table 4-15: Medimeas Corporate Summary
  • QIAGEN N.V.
    • Table 4-16: QIAGEN Corporate Summary
    • Table 4-17: QIAGEN Revenue History, 2017-2023 ($ million, estimated)
  • Roche Diagnostic (Roche Tissue Diagnostics)
    • Table 4-18: Roche Diagnostic Corporate Summary
    • Table 4-19: Roche Revenue History ($ million, estimated)
    • Figure 4-5: Roche Diagnostic Performance, Full Year 2022 and 2023 (CHF Mn)
  • Sysmex
    • Table 4-20: Sysmex Corporate Summary
    • Table 4-21: Sysmex Revenue History, 2017-2023 ($ million, estimated)
  • Thermo Fisher Scientific
    • Table 4-22: Thermo Fisher Corporate Summary
    • Table 4-23: Thermo Fisher Revenue History, 2017-2023 ($ million, estimated)